Chorioallantoic membrane measles: development and clinical evaluation of a new further attenuated measles vaccine.
A new, further attenuated measles vaccine, developed by propagation of Edmonston B measles virus in the chorioallantoic membrane in ovo, has been clinically evaluated in children and found to compare favorably with a commercially available product. The vaccine is prepared in chick embryo tissue culture and appears to possess noteworthy stability at 4 C.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D002642:Chick Embryo; D002648:Child; D002675:Child, Preschool; D003364:Costa Rica; D046508:Culture Techniques; D004355:Drug Stability; D005069:Evaluation Studies as Topic; D005321:Extraembryonic Membranes; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007223:Infant; D008297:Male; D008458:Measles Vaccine / Q000009:adverse effects; D008459:Measles virus / Q000254:growth & development*; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000009:adverse effects
D000914:Antibodies, Viral; D008458:Measles Vaccine; D014613:Vaccines, Attenuated